Please login to the form below
Mark Mallon
This page shows the latest Mark Mallon news and features for those working in and with pharma, biotech and healthcare.
China approves Ironwood Pharma’s IBS treatment
The good news coincides with big changes at the US specialist pharma company, with a new CEO, AstraZeneca's Mark Mallon, and a splitting out into two separate companies. ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion. Ironwood and Allergan
Latest news
-
AZ’s Sean Bohen to exit after business overhaul; report
Chief commercial officer Mark Mallon has taken on the CEO role at US biotech Ironwood Pharmaceuticals, while Medimmune research head Bahija Jallal agreed to take the helm of UK biotech company
-
AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
The reshuffle coincides with the departure of two senior leaders: chief commercial officer Mark Mallon, who leaves to become chief executive of US biotech Ironwood Pharmaceuticals, and Bahija Jallal, who leaves
-
Grünenthal buys Zomig rights as AZ slimming drive continues
Mark Mallon, EVP, global product and portfolio strategy at AstraZeneca, said: “Grünenthal is an established partner with expertise in the treatment of pain.
-
AZ agrees to $320m deal for Zoladex
Mark Mallon, executive vice president of global product and portfolio strategy at AZ, said: “This agreement allows us to retain a significant share of the value of Zoladex in the US
-
AstraZeneca sets sights on China with Takeda deal
The company's executive vice president, international - Mark Mallon - said the increased investment "reinforces our commitment to bring innovative medicines from our exciting pipeline of targeted and biological medicines to patients
More from news
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
China: AstraZeneca’s new engine for growth and innovation
AstraZeneca’s Mark Mallon talks to PME about how its long-term investment in China is paying off. ... Mark Mallon is one of the chief architects of AstraZeneca’s current success in China.
-
Biopharma's Future: Made in China
Mark Mallon is executive vice president of Global Product &Portfolio Strategy at AstraZeneca, and before that spent many years as the company’s head of China and then the wider Asia ... AZ's Mark Mallon. “We have built the right culture there,”
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
